Opthea (OPT) Competitors

Pliant Therapeutics (NASDAQ:PLRX) and Opthea (NASDAQ:OPT) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their community ranking, institutional ownership, dividends, earnings, risk, analyst recommendations, valuation, profitability and media sentiment.

Is PLRX or OPT more profitable?

Opthea's return on equity of 0.00% beat Pliant Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pliant Therapeutics	N/A	-48.91%	-41.09%
Opthea	N/A	N/A	N/A

Do analysts rate PLRX or OPT?

Pliant Therapeutics presently has a consensus target price of $40.57, indicating a potential upside of 226.40%. Opthea has a consensus target price of $12.00, indicating a potential upside of 270.37%. Given Opthea's higher possible upside, analysts plainly believe Opthea is more favorable than Pliant Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pliant Therapeutics	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	3.11
Opthea	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the media prefer PLRX or OPT?

In the previous week, Opthea had 4 more articles in the media than Pliant Therapeutics. MarketBeat recorded 7 mentions for Opthea and 3 mentions for Pliant Therapeutics. Pliant Therapeutics' average media sentiment score of 0.90 beat Opthea's score of 0.45 indicating that Pliant Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pliant Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Opthea	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has better earnings & valuation, PLRX or OPT?

Pliant Therapeutics has higher revenue and earnings than Opthea.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pliant Therapeutics	$1.58M	478.74	-$161.34M	-$3.34	-3.72
Opthea	$124.67K	1,517.65	-$220.24M	N/A	N/A

Does the MarketBeat Community prefer PLRX or OPT?

Pliant Therapeutics received 59 more outperform votes than Opthea when rated by MarketBeat users. Likewise, 74.26% of users gave Pliant Therapeutics an outperform vote while only 51.61% of users gave Opthea an outperform vote.

Company	Underperform	Outperform
Pliant Therapeutics	Outperform Votes 75 74.26%	Underperform Votes 26 25.74%
Opthea	Outperform Votes 16 51.61%	Underperform Votes 15 48.39%

Which has more risk and volatility, PLRX or OPT?

Pliant Therapeutics has a beta of 1.08, indicating that its stock price is 8% more volatile than the S&P 500. Comparatively, Opthea has a beta of 1.15, indicating that its stock price is 15% more volatile than the S&P 500.

Do insiders & institutionals have more ownership in PLRX or OPT?

97.3% of Pliant Therapeutics shares are owned by institutional investors. Comparatively, 56.0% of Opthea shares are owned by institutional investors. 6.4% of Pliant Therapeutics shares are owned by insiders. Comparatively, 3.2% of Opthea shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Pliant Therapeutics beats Opthea on 10 of the 16 factors compared between the two stocks.